Decentralised clinical trials: bringing research to the patient
For decades, patients travelled to research. A quiet redesign is teaching research to travel to patients — and regulators have laid out how to do it well.
Geography has always shaped who joins clinical trials. Decentralised approaches — telehealth visits, home nursing, local laboratories, direct-to-patient supply and connected devices — reduce that constraint by letting trial activities happen where participants live. The approach reached regulatory maturity in 2024, when the US Food and Drug Administration finalised guidance on conducting clinical trials with decentralised elements, offering sponsors a clear framework for designing them responsibly.[1]
What decentralisation changes
- Participation widens. Lower travel burden opens trials to working adults, carers, rural communities and less-mobile patients — improving both fairness and generalisability.
- Data becomes continuous. Connected devices capture outcomes in daily life, complementing scheduled visits with real-world texture.
- Retention improves where burden falls. Convenience is not a luxury; it is a scientific variable that shapes completeness of follow-up.
The craft it demands
Hybrid trials are operationally richer than site-only designs: home visits to coordinate, devices to provision and support, data flows to validate, and oversight to maintain across distributed activities. None of this is a barrier — it is a skills agenda. Protocol designers learn to match each activity to its best setting; project managers orchestrate more moving parts; monitors adapt quality oversight to distributed evidence.
A long prologue, then a leap
Elements of decentralisation are older than the label. Postal follow-up, telephone assessments and site-less “direct-to-participant” studies were being piloted years before 2020 — but they remained curiosities at the edge of an industry built around the investigative site visit. The pandemic converted the edge into the mainstream in a single season: with clinics closed, sponsors and regulators worldwide authorised remote consent, home delivery of investigational products, televisits and local laboratory draws to keep trials alive — and discovered that much of it worked. Regulatory guidance has since consolidated the lessons, moving decentralised elements from emergency accommodation to durable, quality-managed options in the trialist’s toolkit.
The deeper significance is philosophical. For decades, participation in research implicitly required patients to organise their lives around the trial. Decentralisation reverses the default: the trial organises itself around the patient’s life — and in doing so reaches people whom distance, work, caregiving or disability had always excluded.
Designing the hybrid well
- Element by element, risk by risk. Mature teams do not ask “decentralised or not?” but which components — consent, dosing, assessments, monitoring — can move off-site for this protocol without compromising data integrity or safety.
- Fit-for-purpose endpoints. Remote and sensor-based measures validated for the context of use, with clear provenance from device to database.
- The participant experience engineered. Technology support, flexible scheduling and a single human point of contact — the operational courtesies that decide retention.
- Investigator oversight preserved. Distributed activity, undiminished responsibility: the delegation log, training and escalation paths must be as rigorous as any site’s.
- Data flows mapped end to end. Every remote element adds a vendor, a transfer and a reconciliation point; quality-by-design thinking keeps the map coherent.
Looking ahead
The steady state emerging is neither fully remote nor traditionally site-bound but deliberately hybrid — protocols composed from a menu of delivery options, chosen by evidence needs and participant preference. That composition skill, spanning operations, regulation and technology, is the new craft of clinical research, and the professionals who master it are already among the field’s most sought-after.
The competence link: sponsors and CROs increasingly seek trial professionals fluent in decentralised operations — a capability that now differentiates teams and careers alike.
Where EUSTM fits
The EUSTM Academy’s Professional Certification in Clinical Research (PCCR) grounds the scientific and ethical fundamentals, while the Professional Certification in Clinical Project Management (PCCPM) addresses the orchestration skills that make modern, patient-centred trials run beautifully.
References
- Conducting Clinical Trials With Decentralized Elements — guidance for industry. US Food and Drug Administration (2024). www.fda.gov
Disclaimer. This Expert Insight is provided by EUSTM for general informational and educational purposes only. It does not constitute medical, clinical, legal, regulatory or other professional advice, and it should not be relied upon as the basis for clinical, regulatory or business decisions. While care is taken in preparing this content, EUSTM makes no representation or warranty as to the accuracy, completeness or currency of any scientific, medical or other statements, and accepts no liability arising from the use of this content. Readers should consult the cited sources, the current official guidance of the relevant authorities and frameworks, and appropriately qualified professionals in their own jurisdiction. References to third-party organisations, publications or frameworks are for information only and do not imply affiliation or endorsement.
← All Expert Insights